Key Highlights

  • Mesoblast has achieved its target of at least 300 patients treated in the pivotal Phase 3 MSB-DR004 randomised controlled trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease.
  • The trial aims to confirm the durable pain reduction seen from a single intra-discal injection of rexlemestrocel-L in the earlier MSB-DR003 trial, with topline results expected in mid-calendar-year 2027.
  • Rexlemestrocel-L holds Regenerative Medicine Advanced Therapy designation from the US FDA for chronic low back pain due to degenerative disc disease, providing eligibility for priority review once a Biologics License Application is filed.
  • Commercial manufacturing is proceeding in parallel with the trial, with the company stating this is intended to support a regulatory filing as soon as possible after topline results are read out.

Mesoblast Limited (ASX:MSB; Nasdaq:MESO) has announced that it has reached its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomised controlled trial evaluating rexlemestrocel-L for chronic low back pain associated with degenerative disc disease, a milestone the company says ensures the trial is well powered for a successful outcome.

Trial Design and Objectives

MSB-DR004 is a 300-patient randomised, placebo-controlled confirmatory Phase 3 trial evaluating rexlemestrocel-L, Mesoblast's second-generation allogeneic, STRO3-immunoselected stromal cell product candidate, delivered in combination with hyaluronic acid as an intra-discal injection into the lumbar disc. The trial is enrolling patients with chronic low back pain due to inflammatory degenerative disc disease of less than five years' duration across multiple sites in the United States. The primary endpoint is powered to demonstrate a significant difference in reduction of low back pain at 12 months between rexlemestrocel-L and sham controls, a design the FDA has previously agreed, with secondary endpoints covering improvements in function, quality of life and cessation of pain medication, including opioids.

Building on Earlier Phase 3 Results

The current trial is designed to confirm findings from Mesoblast's earlier MSB-DR003 trial, in which the 12-month primary endpoint of pain reduction was successfully met, alongside observed improvements in quality of life and function and reported reductions in opioid use. Given that chronic low back pain accounts for approximately half of prescription opioid usage in the United States, a particular focus of the trial is on outcomes for patients using opioid medication, including rates of cessation.

Regulatory Pathway and Manufacturing

Rexlemestrocel-L has been granted Regenerative Medicine Advanced Therapy designation by the US FDA for the treatment of chronic low back pain due to degenerative disc disease. This designation carries the benefits of Breakthrough and Fast Track designations, including rolling review and eligibility for priority review once a Biologics License Application is filed. Mesoblast Chief Executive Silviu Itescu said commercial manufacturing is proceeding in parallel with the trial, with the intention of filing for approval as soon as possible following the topline results readout, which is expected in mid-calendar-year 2027 after the last treated patient completes 12 months of follow-up.

Market Opportunity and Disease Burden

Chronic low back pain due to inflammatory degenerative disc disease affects an estimated more than seven million people in the United States alone, and the company describes back pain as a leading cause of disability among Americans under the age of 45. Mesoblast has characterised the indication as a potential blockbuster opportunity, citing potential peak annual revenue exceeding US$10 billion even at single-digit market penetration, though this figure represents a company estimate rather than a guaranteed commercial outcome, and remains contingent on the trial's success and subsequent regulatory approval.

Cell Therapy Manufacturing Considerations

Allogeneic, or off-the-shelf, cell therapies such as rexlemestrocel-L are manufactured industrially from donor-derived cells rather than a patient's own tissue, an approach intended to support consistent product quality and scalable supply once approved. Running commercial-scale manufacturing in parallel with a pivotal trial, as Mesoblast describes doing here, is intended to compress the time between a successful data readout and product availability, though it also means the company is investing capital ahead of confirmed trial success.

Share Market Context

Mesoblast shares were recently trading at $2.32, down 1.06% on the day, according to intraday market data. As a clinical-stage biopharmaceutical company with one approved product, Ryoncil, already generating commercial revenue, Mesoblast's share price is likely to remain sensitive to progress across its broader pipeline, including this pivotal chronic low back pain program, ahead of the expected mid-2027 topline readout.

Conclusion

Reaching the 300-patient enrolment target in the MSB-DR004 trial represents a procedural milestone that moves Mesoblast a step closer to its expected mid-2027 topline data readout for rexlemestrocel-L in chronic low back pain. The trial's outcome remains to be determined, and as with any pivotal clinical study, full enrolment does not guarantee that the primary endpoint will be met when data matures. Given the size of the addressable patient population and the company's parallel investment in commercial manufacturing, investors following Mesoblast may wish to monitor further enrolment and trial progress updates in the lead-up to the 2027 results.